Perchellet Elisabeth M, Sperfslage Bonnie J, Wang Yang, Huang Xiaodong, Tamura Masafumi, Hua Duy H, Perchellet Jean-Pierre
Anti-Cancer Drug Laboratory, Division of Biology, Ackert Hall, Kansas State University, Manhattan 66506-4901, USA.
Anticancer Drugs. 2002 Jul;13(6):567-81. doi: 10.1097/00001813-200207000-00003.
In contrast to their inactive parent compound triptycene (code name TT0), several new synthetic analogs (TT code number) have antileukemic activities and remain effective in daunorubicin (DAU)-resistant tumor sublines in vitro. Among variously substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetraones, a total of six lead antitumor compounds have been identified, and their code names are TT2, TT13, TT16, TT19, TT21 and TT24. These active antitumor triptych structures have bisquinone functionality, and various bromo, methoxy, methylamino and/or dimethylamino substitutions with or without longer alkyl chains on the amino function. Like the anthracycline quinone antibiotic DAU, these triptycene (TT) bisquinones also inhibit DNA synthesis and induce DNA cleavage in relation with their cytotoxic activities, but have the additional advantage of blocking the cellular transport of purine and pyrimidine nucleosides, an effect which DAU cannot do. As demonstrated by intact chromatin precipitation and agarose gel electrophoresis, the ability of TT bisquinones and DAU to induce DNA fragmentation is biphasic with a peak that shifts to lower concentrations with increasing times of drug exposure. The most effective lead antitumor compound, TT24, induces DNA cleavage in the same concentration-dependent manner as DAU at 24 h (similar peak in response to 1.6 microM) and is nearly equipotent to DAU against L1210 tumor cell viability at day 4 (IC50 values of TT24 and DAU: 48 and 25 nM, respectively). The mechanism by which TT24 induces DNA fragmentation is inhibited by actinomycin D, cycloheximide, benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone, benzyloxycarbonyl-Ile-Glu-Thr-Asp-fluoromethyl ketone, N-tosyl-L-phenylalanine chloromethyl ketone and ZnSO4, suggesting that TT bisquinones trigger apoptosis by caspase and endonuclease activation. Since TT24 is cytotoxic in the nanomolar range of DAU, but might have a more versatile mechanism of action than DAU in wild-type and multidrug-resistant tumor cells, this new class of DNA-damaging quinone antitumor drugs inhibiting nucleoside transport might be valuable to develop new means of polychemotherapy.
与其无活性的母体化合物三蝶烯(代号TT0)不同,几种新的合成类似物(TT代号)具有抗白血病活性,并且在体外对柔红霉素(DAU)耐药的肿瘤亚系仍然有效。在各种取代的9,10-二氢-9,10-[1,2]苯并蒽-1,4,5,8-四酮中,总共鉴定出六种先导抗肿瘤化合物,它们的代号分别为TT2、TT13、TT16、TT19、TT21和TT24。这些具有活性的抗肿瘤三蝶烯结构具有双醌官能团,并且在氨基官能团上有各种溴、甲氧基、甲氨基和/或二甲氨基取代,有或没有较长的烷基链。与蒽环类醌抗生素DAU一样,这些三蝶烯(TT)双醌也抑制DNA合成并与其细胞毒性活性相关地诱导DNA裂解,但具有阻断嘌呤和嘧啶核苷细胞转运的额外优势,而DAU无法做到这一点。通过完整染色质沉淀和琼脂糖凝胶电泳证明,TT双醌和DAU诱导DNA片段化的能力是双相的,随着药物暴露时间的增加,峰值向较低浓度移动。最有效的先导抗肿瘤化合物TT24在24小时时以与DAU相同的浓度依赖性方式诱导DNA裂解(对1.6 microM的反应有相似的峰值),并且在第4天对L1210肿瘤细胞活力与DAU几乎等效(TT24和DAU的IC50值分别为48和25 nM)。放线菌素D、环己酰亚胺、苄氧羰基-Val-Ala-Asp-氟甲基酮、苄氧羰基-Ile-Glu-Thr-Asp-氟甲基酮、N-甲苯磺酰基-L-苯丙氨酸氯甲基酮和ZnSO4抑制TT24诱导DNA片段化的机制,这表明TT双醌通过半胱天冬酶和核酸内切酶激活触发细胞凋亡。由于TT24在DAU的纳摩尔范围内具有细胞毒性,但在野生型和多药耐药肿瘤细胞中可能具有比DAU更通用的作用机制,这类抑制核苷转运的新型DNA损伤醌类抗肿瘤药物可能对开发新的联合化疗方法具有重要价值。